Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01207440

Chronic Myeloid Leukemia Ph+ Acute Lymphoblastic Leukemia

COMPLETED PHASE2

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

NCT02467270

Myeloid Leukemia, Chronic, Chronic Phase

COMPLETED PHASE2

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

NCT01570868

Leukemia

TERMINATED PHASE2

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

NCT04233346

Chronic Myeloid Leukemia Acute Lymphoblastic Leukemia

ACTIVE_NOT_RECRUITING PHASE2

Expanded Access Program of Ponatinib

NCT01592136

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

APPROVED_FOR_MARKETING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Myelogenous Leukemia Hematologic Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ponatnib

Comparison of different dosages of ponatinib given orally once per day.

Group Type EXPERIMENTAL

Ponatinib

Intervention Type DRUG

Comparison of different dosages of drug given orally once per day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ponatinib

Comparison of different dosages of drug given orally once per day.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AP24534 Iclusig

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female ≥ 18 years old
* Diagnosed hematologic malignancy (other than lymphoma) that has relapsed or is refractory to standard care or for which no standard care is available or acceptable
* Able to give written informed consent
* ECOG performance status ≤ 2
* BSA ≥ 1.5 m² (first cohort only)
* Minimum life expectancy of 3 months or more
* Adequate renal function defined as serum creatinine \<1.5× upper limit of normal (ULN) for institution
* Adequate hepatic function (defined as: Total bilirubin \<1.5 × ULN for institution; ALT and AST \<2.5 × ULN for institution \[\<5 X ULN if liver involvement with leukemia\]; Prothrombin time \<1.5 × ULN)
* Ability to comply with study procedures in the Investigator's opinion
* Adequate cardiac function defined as ejection fraction (EF) \>40% by any method of the investigator's choice
* Normal QTcF interval on screening ECG evaluation, defined as QTcF of \<450 ms.
* For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment
* Female patients who are of childbearing potential must agree to use an effective form of contraception with their sexual partners throughout participation in this study

Exclusion Criteria

* Have had cytotoxic chemotherapy or radiotherapy within 21 days prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 28 days earlier with the exception of alopecia
* Received any other investigational agents or have received an investigational agent within 14 days of starting ponatinib
* Malabsorption syndrome or other illness which could affect oral absorption
* Significant uncontrolled cardiac disease
* Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram.
* Uncontrolled hypertension (Diastolic BP \>100 mmHg; Systolic \>150 mmHg)
* Uncontrolled intercurrent illness
* Pregnant
* Known infection with HIV
* Autologous or allogeneic stem cell transplant \< 3 months prior to enrollment; any evidence of ongoing graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy
* Another primary malignancy within the past 3 years
* Any condition or illness which, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the drug
* Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram
* Major surgery (with the exception of intravenous catheter placement or bone marrow biopsy) within 14 days prior to initiating ponatinib therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No